Imaging inflammatory bowel disease by Vassallo, Pierre
inflammatory bowel disease (IBD) refers to a group of idiopathic conditions of the gastrointestinal tract, the most common of which are Crohn’s disease and ulcerative colitis 
(uC). Approximately one in every four to six patients with IBD 
presents in childhood or adolescence. The incidence of IBD has 
been increasing over the past 40 years. 
Crohn’s disease is a chronic inflammatory disease of the 
gastrointestinal tract that is characterized by waxing and waning 
symptoms, transmural inflammation of the bowel wall (i.e. 
all three bowel wall layers), and skip lesions. It may effect any 
portion of the gastrointestinal tract, in contrast to uC which 
only effects the colon . uC lesions are also contiguous and do 
not penetrated beyond the mucosal layer unlike, Crohn’s disease.
IBD can be diagnosed or monitored using a variety of 
methods, including clinical or hematologic assessment, 
endoscopy, and imaging. In recent years, an increase in the 
number of methods used to visualize the bowel has become 
available, including capsule endoscopy, Ct enterography, and 
MR enterography, with each study having its advantages and 
disadvantages.
Ct or MR enterography is tailored to evaluate the small 
bowel and its mucosa. Both studies provide exquisite detail 
of the bowel wall, including its thickness and mucosa, while 
also allowing detection of the extraenteric manifestations and 
complications of IBD.
Both Ct and MR enterography provide high quality small 
bowel imaging. Ct enterography has the advantages of  better 
spatial resolution, fewer motion artifacts, lower cost, shorter 
examination times and increased tolerance by claustrophobic 
patients. on the other hand, MR enterography has the advantage 
of not using ionizing radiation; this is therefore preferable in 
children and in pregnant women. MR enterography offers also 
higher contrast resolution and better evaluation of perianal 
disease, while also allowing assessment of peristalsis through 
dynamic imaging. 
When comparing Ct or MR enterography to traditional 
small bowel barium follow-through exam, the former are more 
accurate in detecting IBD, while Ct enterography performed 
on new generation scanners that use iterative reconstruction 
technologies, exposes the patient to a smaller radiation dose than 
a small bowel barium exam. 
Small bowel endoscopy rarely covers the whole small bowel 
and therefore misses a significant number of cases with small 
bowel inflammatory disease. Capsule endoscopy is performed 
with an 11 x 27mm capsule that is swallowed by the patient and 
that records images as it passes through the gastrointestinal tract. 
It is superior to all other tests for detecting mucosal changes, 
however it is unable to detect transmural extent of disease and 
extraenteric manifestations. The capsule is difficult to swallow 
particularly in children. In addition, due to the frequent presence 
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Figure 1. Coronal Ct enterographic image showing 
multiple areas of bowel wall thickening throughout 
the abdomen (arrows) in this patient with Crohn’s 
disease. 
Figure 2. Coronal Ct enterographic image showing 
mucosal enhancement and mural stratification 
(white arrow) as well as engorged mesenteric blood 
vessels (vasa recta) (black arrows) in this patient 
with Crohn’s disease.
Figure 3. MR enterographic image shows bowel 
wall thickening of the descending colon (white 
arrow) and wispy increased signal intensity in the 
surrounding pericolonic fat (black arrow).
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of bowel strictures particularly in Crohn’s disease, there is a 
high risk of capsule retention (8%), which would consequently 
require open surgery further increasing the risk of complicating 
structures, fistulae and abscess formation. Thus a barium study 
is required prior to capsule endoscopy in order to exclude 
strictures and minimize the risk of capsule retention. 
The technique for performing Ct or MR enterography 
is quite complex and is beyond the scope of this article. The 
imaging findings are similar on both Ct and MR imaging; 
they can be divided into (1) intestinal and (2) extra-intestinal 
findings. 
1. inTesTinal finDings
The intestinal findings include bowel wall thickening 
(bowel	wall	thickness	>3mm	in	a	distended	loop),	mucosal	
enhancement, mural layering, skip lesions, luminal narrowing/
strictures and fistula. Bowel wall thickening (Fig 1) is the most 
common finding in IBD particularly in Crohn’s disease. Mucosal 
enhancement is the strongest indicator of acute inflammation 
and is often accompanied by mural stratification (Fig 2). Bowel 
wall thickening is also clearly evident on MR enterography  
(Fig 3) as is mucosal enhancment (Fig 4). Mural stratification 
may also be the result of fat deposition in between the mucosa 
and serosa; this occurs in chronic IBD and can be confirmed 
with fat suppression techniques on MR enterography. Skip 
lesions are discontinuous areas of inflammation in either 
the small bowel or colon and are characterized by either 
mucosal enhancement or bowel wall thickening; these are 
pathognomonic of Crohn’s disease (Fig 4). 
Diffusion-weighted imaging (DWI) is a special technique 
that is available on MR imaging, which measures the diffusivity 
of extracellular water. Acutely inflammed bowel has an excess 
Figure 4. Coronal post-IV contrast t1-weighted 
MR enterographic image showing discontinuous 
regions of bowel wall thickening and mucosal 
enhancement (arrows). 
Figure 5. Coronal diffusion-weighted image with 
background body shows an S-shaped area of 
restricted diffusion corresponding to the terminal 
ileum (arrows).
Figure 6. Coronal Ct enterographic image 
showing  narrowing of the lumen of the terminal 
ileum (white arrow) in Crohn’s disease.
Figure 7. Axial contrast enhanced t1-weighted 
image shows a strictured segment of small bowel 
(white arrow) and dilatation of the more proximal 
small bowel (black arrow).
Figure 8. Axial t1-weighted MR entrograph shows 
a fistula between the colon and uterus (white 
arrow), a short-segment stricture (arrowhead) just 
proximal to the fistula and more proximal  small 
bowel dilatation (black arrow).
Figure 9. oblique coronal Ct enterographic image 
shows abnormal bowel wall thickening, mucosal 
hyperenhancement of the terminal ileum and 
engorgment of the vasa recta (arrows) creating the 
comb sign. 
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of extracellular fluid that naturally has a high diffusivity; this is 
well seen on DWI and can be used to identify active bowel wall 
inflammation (Fig 5).
Luminal narrowing and strictures may be identified either 
through actual narrowing of the luminal diameter (Fig 6) or 
indirectly through dilatation of the more proximal bowel loops 
(Fig 7). 
Patients with Crohn’s disease have a 20–40% lifetime 
risk of fistula formation and the most common fistulas are 
enterocutaneous, enteroenteric, and perianal fistulas (Fig 8).
2. exTra-inTesTinal finDings
The extra-intestinal findings include engorgement of 
mesenteric vessels (comb sign), mesenteric infiltration, 
increased mesenteric fat, lymphadenpathy, fluid collections 
(abscess formation) and ascites. engorgement of the vasa recta 
is a finding of active inflammation in IBD and is caused by 
increased blood flow through the vasa recta to inflamed 
segments of bowel; this may result in the comb sign (Fig 9). 
extension of inflammation outside the bowel wall results 
in mesenteric infiltration that appears as fat stranding on 
MR and Ct enterography (Fig 10). An increase in number 
and size of mesenteric lymph nodes (frequently only mildly 
enlarged) is seen in IBD (Fig 11). 
other non-bowel related features, which include gall 
stones, nephrolithiasis, primary sclerosing cholangiitis, 
sacroiliitis and thromboembolism are all detected on 
images obtained during Ct and MR enterography. 
Ct and MR enterography are safe and effective methods 
for diagnosing and evaluating IBD; unlike previous x-ray 
contrast techniques and endoscopy, these methods allow 
radiologists to interpret intestinal and extra-intestinal findings 
that are widespread and which are of great importance in these 
patients.  
Figure 11. Prominent 
mesenteric lymph nodes 
(increase in size and 
number of lymph nodes) 
(arrows) seen on coronal 
Ct enterography.
Figure 10. Fat stranding 
within the pericecal fat 
(arrows) seen on axial Ct 
enterography.
ANNOuNcemeNT 
new PosTgraDuaTe DocToraTe of Pharmacy Programme in euroPe
The university of Malta in collaboration with the university of Illinois in Chicago is launching a new postgraduate Doctorate of Pharmacy programme, PharmD.  The course starts in october 2014 and is intended to attract pharmacists who would like to develop 
their clinical pharmacy and research skills to a doctorate degree while empowering pharmacists to assume leadership roles that will 
drive policies and developments in clinical practice and service that draws on scientific, evidence-based and innovative research. 
The Pharm D course is spread over three years of study (6 semesters).  The first year of study is mainly composed of taught units 
with the second and third years being based primarily on research and clinical experience. The taught programme covers aspects of 
Pharmacotherapeutics, Drug information and statistics, Pharmacoeconomics and Health systems in europe and the uSA. The Clinical 
Experience will be provided through clinical rotations based in different pharmacy settings including hospital, ambulatory care and 
community pharmacy.  The Research modules will lead the candidate to develop critical analysis and literature evaluation within the 
context of translational and applied research in pharmacy. All study-units are delivered jointly by the two universities through lectures, 
distance learning and practice-based learning. This course presents a unique opportunity for pharmacists in all areas to acquire a 
doctorate degree reflecting present and future international developments in pharmacy.
Funding: A number of paid traineeships for a 28 hour per week with a stipend of 1000 euro per month are available in the 
following pharmaceutical areas: hospital, community, procurement, informatics, distribution, regulatory and industrial. For further 
information contact Prof. Lilian M. Azzopardi of the Department of Pharmacy at the uoM on lilian.m.azzopardi@um.edu.mt 
or Prof. Alan Lau from the College of Pharmacy university of Illinois on alanlau@uic.edu. Website:  http://www.um.edu.mt/imp/
courses/doctor-of-pharmacy.   
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